Business Context and Reporting Period
This Form 8-K is a current report filed by AgeX Therapeutics, Inc. (trading symbol: AGE) on May 18, 2022, covering events occurring on May 13, 2022. The company is a Delaware corporation headquartered in Alameda, California, and is classified as an emerging growth company.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial statements or performance metrics.
Material Changes
The primary material change reported is a leadership transition within the Board of Directors:
- Dr. Joanne Hackett was appointed Chairperson of the Board on May 13, 2022.
- Dr. Hackett, who joined the Board in December 2021, serves in a non-executive capacity.
- Dr. Greg Bailey, who served as Chairperson since 2018, will continue as a member of the Board of Directors.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer regarding forward-looking statements, noting that actual results may differ materially from anticipated results due to various risk factors detailed in the company's periodic reports. No specific financial guidance, operational outlook, or new contingencies were disclosed in this document.
Key Facts for Investor Verification
- Confirm the effective date of Dr. Hackett's appointment as Chairperson (May 13, 2022).
- Verify Dr. Bailey's continued role as a non-chairman board member.
- Review the press release filed as Exhibit 99.1 for additional context on the leadership change.
- Note that this filing contains no financial data; refer to the most recent 10-K or 10-Q for financial status.